Expect to See Adakveo or Oxbryta for Some Sickle Cell Patients

March 2020

Adakveo (ah-DAK-vee-oh, crizanlizumab) and Oxbryta (oks-BRYE-tuh, voxelotor) will be new meds for sickle cell disease.

They may be added to hydroxyurea...the first-line option to reduce pain crises, hospitalizations, and possibly improve survival.

And they’ll compete with oral Endari (L-glutamine)...which seems to reduce pain crises and possibly hospitalizations.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote